ArticleBMC pregnancy and childbirth2025
Neonatal outcome in late preterm twin gestation: impact of antenatal corticosteroids therapy before 34 weeks.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effects of antenatal corticosteroid (ACS) exposure before 34 weeks on neonates born in the late preterm period are a subject of controversy. We aimed to investigate the impact of ACS exposure before 34 weeks on neonates of dichorionic diamniotic (DCDA) twins born in the late preterm period.
methodsThis retrospective cohort study included all DCDA twin gestations born at 34.0-36.6 weeks between January 2014 and December 2020 at a single tertiary medical center. Neonatal outcomes were compared between twin gestations treated with ACS before 34 weeks (ACS group) and those not treated with ACS (control group). A sub-analysis examined neonatal outcomes between those treated with ACS within 14 days of delivery and those treated more than 14 days before delivery.
resultsA total of 297 twin gestations were included, with 122 in the ACS group and 175 in the control group. Maternal age, BMI, hypertensive disorders and diabetes mellitus did not differ between the groups. ACS was given for suspected preterm birth (85.2%), fetal growth restriction (4.9%), preeclampsia (3.2%), placental abruption (2.4%), and placenta previa-related bleeding (2.4%). Gestational age (GA) at delivery was lower in the ACS group than in the control group (35.06 ± 0.8 weeks vs. 35.49 ± 0.69 weeks, p < 0.001). The ACS group had higher rates of neonatal admission to the 'neonatal intensive care unit' (NICU)-36.1% vs.16.6%, p < 0.001, and small for gestational age (SGA), 7.2% vs. 9.4%, p = 0.004. By multivariable logistic regression analysis ACS treatment was found to be independently associated with SGA birth (OR 1.997, 95% CI 1.225-3.257, p = 0.006). Within the ACS group, neonates who delivered within 14 days of ACS treatment had higher rates of NICU admission compared to those born > 14 days from ACS treatment (p < 0.004).
conclusionTwin pregnancies that were born in the late-preterm period and were exposed to ACS before 34 weeks, showed increased rates of SGA and neonatal NICU admission. Caution is needed when administering ACS in twin gestations to avoid unnecessary exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.